Plasmablastic lymphoma of the retroperitoneum in an HIV- and HCV-positive patient: Hard to diagnose and harder to treat

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3529-3534

  Dholaria, Bhagirathbhai ^a   Alapat, Daisy ^b   Pandey, Tarun ^b   Agarwal, Abhishek ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

HCV; HIV; Immunohistology; Plasmablastic lymphoma

Indexed keywords

ANTIGEN; CAM 5.2 ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; INTERFERON REGULATORY FACTOR 4; LEUKOSIALIN; SYNDECAN 1; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AFRICAN AMERICAN; ARTICLE; BONE MARROW BIOPSY; CANCER CELL; CANCER LOCALIZATION; CANCER PROGNOSIS; CASE REPORT; CD4 LYMPHOCYTE COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FECES INCONTINENCE; HEPATITIS C; HISTOPATHOLOGY; HOSPICE CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; HYDRONEPHROSIS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; INFERIOR CAVA VEIN OBSTRUCTION; INFERIOR VENA CAVAL COMPRESSION; KARYOTYPE; LIMB WEAKNESS; LYMPHADENOPATHY; MALE; MALE HOMOSEXUAL; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE UROPATHY; ONCOGENE C MYC; PARAAORTIC LYMPH NODE; PERCUTANEOUS NEPHROSTOMY; PLASMABLASTIC LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADICULOPATHY; RENAL REPLACEMENT THERAPY; RETROPERITONEAL CANCER; RETROPERITONEUM PLASMABLASTIC LYMPHOMA; SACRAL RADICULOPATHY; TREATMENT REFUSAL; TUMOR BIOPSY; TUMOR DIFFERENTIATION; UREMIC POLYNEUROPATHY; URINALYSIS; URINE VOLUME; VIRUS LOAD; DIFFERENTIAL DIAGNOSIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARGE CELL LYMPHOMA; MULTIPLE MYELOMA; PATHOLOGY; PLASMACYTOMA; RETROPERITONEAL TUMOR; VIROLOGY;

ADULT; DIAGNOSIS, DIFFERENTIAL; HEPATITIS C; HIV INFECTIONS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MULTIPLE MYELOMA; NEOPLASMS, PLASMA CELL; RETROPERITONEAL NEOPLASMS;

EID: 84880253912     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0248-2     Document Type: Article

References (24)

1. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol. 2005;84(1):1-12. doi: 10.1007/s00277-004-0939-7.
2. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD [database on the Internet]1975-2008. Available from: http://seer.cancer.gov/csr/1975-2008/. Accessed 22 Dec 2011.
3. Carbone A, Gaidano G, Gloghini A, Ferlito A, Rinaldo A, Stein H. AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. Ann Otol Rhinol Laryngol. 1999;108(1):95-9.
4. Teruya-Feldstein J. Diffuse large B-cell lymphomas with plasmablastic differentiation. Curr Oncol Rep. 2005;7(5):357-63.
5. Antonino Carbone AG. Plasmablastic lymphoma: one or more entities? Am J Hematol. 2008;83(10):1.
6. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83(10):804-9. doi: 10.1002/ajh.21250.
7. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51(11):2047-53. doi: 10.3109/10428194.2010.516040.
8. Takahashi Y, Saiga I, Fukushima J, Seki N, Sugimoto N, Hori A, et al. Plasmablastic lymphoma of the retroperitoneum in an HIV-negative patient. Pathol Int. 2009;59(12):868-73. doi: 10.1111/j.1440-1827.2009.02457.x.
9. Valera A, Balague O, Colomo L, Martinez A, Delabie J, Taddesse-Heath L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34(11):1686-94. doi: 10.1097/PAS.0b013e3181f3e29f.
10. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010;23(7):991-9. doi: 10.1038/modpathol.2010.72.
11. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113(6):1213-24. doi: 10.1182/blood-2008-09-180315.
12. Qing X, Sun N, Chang E, French S, Ji P, Yue C. Plasmablastic lymphoma may occur as a high-grade transformation from plasmacytoma. Exp Mol Pathol. 2011;90(1):85-90. doi: 10.1016/j.yexmp.2010.10.007.
13. Mizorogi F, Hiramoto J, Nozato A, Takekuma Y, Nagayama K, Tanaka T, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin's lymphoma. Intern Med. 2000;39(2):112-7.
14. Machida K, Tsukiyama-Kohara K, Sekiguch S, Seike E, Tone S, Hayashi Y, et al. Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins. Gastroenterology. 2009;137(1):285-96, 96 e1-11. doi: 10.1053/j.gastro.2009.03.061.
15. Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, Maestre L, Sanchez-Verde L, Roncador G, et al. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica. 2010;95(8):1342-9. doi: 10.3324/haematol.2009.016113.
16. Montes-Moreno S, Roncador G, Maestre L, Martinez N, Sanchez-Verde L, Camacho FI, et al. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood. 2008;111(1):351-8. doi: 10.1182/blood-2007-06-094151.
17. Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18(6):806-15. doi: 10.1038/modpathol.3800355.
18. Choi Q, Kim HK. Plasmablastic plasma cell myeloma mimicking plasmablastic lymphoma. Korean J Hematol. 2010;45(4):223. doi: 10.5045/kjh.2010.45.4.223.
19. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma. Oncologist. 2010;15(3):293-9. doi: 10.1634/ theoncologist.2009-0304.
20. Simonitsch-Klupp I, Hauser I, Ott G, Drach J, Ackermann J, Kaufmann J, et al. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia. 2004;18(1):146-55. doi: 10.1038/sj.leu.2403206.
21. NCCN Practice Guidelines in Oncology. Non-Hodgkins lymphomas. national comprehensive cancer network. (2011) http://www.nccn.org/professionals/ physician-gls/PDF/nhl.pdf. Accessed 16 Jan 2012.
22. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069-76. doi: 10.1182/blood-2009-01-199679.
23. Bibas M, Grisetti S, Alba L, Picchi G, Del Nonno F, Antinori A. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol. 2010;28(34):e704-8. doi: 10.1200/jco.2010.30.0038.
24. Bose P, Thompson C, Gandhi D, Ghabach B, Ozer H. AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol. 2009;82(6):490-2. doi: 10.1111/j.1600-0609.2009.01235.x.